When evaluating a new asset — start by understanding its molecular profile and mechanism of action, then map the cross-functional decision points that will shape its development path, assess how it differentiates against competing programs in the landscape, and close with the evidence base from key guidelines to ground your strategic decisions.
Each one shows the prompt we'd actually run, a snippet of what Cheiron returns, and a link to the full grounded response with citations.
New to Cheiron? Start with Getting Started with Cheiron and How Cheiron Grounds Answers (Deep Citations) — they explain why every answer below is auditable back to it's source.
Profile a Drug or Target
Describe molecular and product characteristics
Example question:
”Describe the molecular structure, binding characteristics, and modality of trastuzumab deruxtecan, including how the ADC design influences its pharmacological behavior.”
Cheiron’s response:
Trastuzumab deruxtecan is a HER2-directed antibody–drug conjugate that couples a humanized anti-HER2 IgG1 antibody to a topoisomerase I inhibitor payload, DXd, through a cleavable tetrapeptide linker. Its ADC architecture is designed to bind HER2-expressing tumor cells, internalize, release a membrane-permeable cytotoxic payload after linker cleavage, and thereby...
Tip: Unpack the structural design, binding properties, and modality of a compound — and understand how those characteristics drive its pharmacological behavior and clinical rationale.
Understand the Product Lifecycle
Map Cross-Functional Decision Points
Example question:
”Map how clinical, CMC, regulatory, and commercial functions interact across the product lifecycle (from early development through post-marketing) highlighting key decision points at each stage.”
Cheiron’s response:
A practical lifecycle operating model is a stage-gate system where clinical evidence, CMC/product quality, regulatory strategy, and market-facing strategy are developed together rather than sequentially. ICH E8 frames development planning as covering the entire product lifecycle, with earlier study results informing later studies and emerging data often changing the development strategy...
Tip: Trace how clinical, CMC, regulatory, and commercial functions interact across the development lifecycle, and identify the inflection points where cross-functional alignment is critical.
Explore the Competitive Landscape
Assess Differentiation Strategies Across Competing Programs
Example question:
”Compare pipeline programs in systemic lupus erythematosus by mechanism of action and clinical development stage.”
Cheiron’s response:
The SLE pipeline represented here is broad, spanning late-stage oral immunomodulators, B-cell and plasma-cell–directed biologics/cell therapies, type I interferon or pDC-directed approaches, and several mechanism-not-specified trial programs. The most advanced actively studied mechanisms include S1P1 modulation, TYK2 inhibition, BDCA2/pDC targeting...
Tip: Map competing programs by modality, mechanism, and development stage to identify where your asset can establish a distinct and defensible position.
Understand Scientific Literature and Guidelines
Extract Key Recommendations from Relevant Guidelines
Example question:
”Extract key recommendations from major guidelines on biomarker testing in non-small cell lung cancer.”
Cheiron’s response:
Major NSCLC biomarker-testing guidance converges on early, broad, tissue-sparing biomarker assessment, especially in advanced disease, with NGS preferred over serial single-gene testing when feasible, PD-L1 IHC required for immunotherapy selection, and liquid biopsy/cytology used as adjuncts when tissue is limited or...
Tip: Pull the most actionable guidance from major clinical or regulatory guidelines to inform development decisions, trial design, or evidence requirements.
These examples are only a starting point. To explore additional questions, see Ask Cheiron for guidance on writing questions and reviewing answers.